Last reviewed · How we verify
OCU400 High Dose
At a glance
| Generic name | OCU400 High Dose |
|---|---|
| Sponsor | Ocugen |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study to Assess the Safety and Efficacy of OCU400 for Retinitis Pigmentosa and Leber Congenital Amaurosis (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCU400 High Dose CI brief — competitive landscape report
- OCU400 High Dose updates RSS · CI watch RSS
- Ocugen portfolio CI